Regenicin Appoints Amgen Co-founder Dr. Joseph Rubinfeld to Board of Directors
NEW YORK, Aug. 24 /PRNewswire-FirstCall/ -- Regenicin, Inc. (OTC Bulletin Board: WDSTD), a clinical-stage biotechnology company, announced today that Dr. Joseph Rubinfeld, one of the four original founders of Amgen, Inc., has agreed to join the company's board of directors. Dr. Rubinfeld will be instrumental to assisting the company's commercialization efforts of PermaDerm™, Regenicin's proprietary autologous cultured skin substitute intended to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds and a variety of plastic surgery procedures.
In addition to his efforts in founding Amgen, Dr. Rubinfeld has a forty-year history in pharmaceutical and consumer product development. His accomplishments include the creation of the multi-billion dollar antibiotic Amoxicillin as well as the first synthetic biodegradable detergent. He has obtained over 100 patents during his distinguished career.
Commenting on his decision to join Regenicin, Dr. Rubinfeld stated, "With the recent acquisition of the rights to this revolutionary technology, Regenicin is in a position to be the only company in the world capable of quickly growing and grafting a person's own skin. This is a critical development for the multi-billion dollar treatment market for burns and other wounds that are currently dependent on cadaver and pig skin," said Dr. Rubinfeld. "These methods often have high rejection rates compared to virtually no rejection issues when a person's own skin is being used for grafting. I look forward to helping the team at Regenicin navigate through the final hurdles toward commercialization of this life improving technology."
Dr. Rubinfeld began his career